Work

131P The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)

Year: 2024

Type: article

Abstract: PD-1 inhibitors plus chemotherapy was approved as standard 1L treatment for advanced HER2-negative G/GEJA, but its outcomes remain poor in patients (pts) with low PD-L1 expression. For advanced HER2-positive G/GEJA, integrating immunotherapy with trastuzumab and chemotherapy has shown a significant improvement in progression-free survival (PFS) and overall survival (OS). Cadonilimab, a PD-1/CTLA-4 bispecific antibody, has demonstrated its efficacy and safety in previously untreated advanced G/GEJA pts, even those with PD-L1 CPS<5 in a phase III study.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100760

Authors: W. Yang, X. Li, C. Zhang, J. Gao, Y. Shi

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170

Funders: National Research Foundation, National Research Foundation of Korea